SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as investors debate the potential for a transformative buyout following reports of massive pharmaceutical M&A activity in the oncology space. Community discussions are highly polarized, with bulls highlighting the trial's prolonged survival timeline as evidence of therapeutic success, while bears express concern over the company's financial structure and the potential for a binary clinical outcome.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is generating intense community speculation as investors anticipate imminent Phase 3 VELA data, fueling intense M&A discussions and optimism that sonelokimab will emerge as a best-in-class treatment for hidradenitis suppurativa. The community is closely watching for a potential data release to coincide with upcoming investor presentations, which many believe could trigger a massive rerating event due to the drug's demonstrated efficacy and superior safety profile over existing competition.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

TQQQ is trending as market participants closely monitor geopolitical tensions in the Middle East and their potential impact on energy markets and interest rate sentiment. The community is actively debating the durability of the AI-driven tech rally amidst record market highs and ongoing economic uncertainty.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk Corp (SNDK) is witnessing extreme volatility and a parabolic rally, fueled by intense investor enthusiasm surrounding AI-driven memory storage demands and persistent supply chain bottlenecks. The stock has become a primary focal point for momentum traders, sparking heated debates between bulls banking on a structural supercycle and bears warning of a speculative bubble due to its rapid, historic price appreciation.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is attracting intense investor attention following a significant clinical data release for Lupkynis and increased share accumulation by CEO Kevin Tang. While the community is actively debating the potential for an imminent buyout or strategic acquisition, sentiment remains divided between hopeful longs anticipating a catalyst-driven surge and skeptics frustrated by a lack of direct management communication.

Butterfly Network, Inc. designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment. It develops and provides a whole-body portable ultrasound scanner called the iQ Device and related hosted, web-based application, application programming interfaces and platform services, which the firm offer to physicians or other licensed health care providers. Its products include iQ+ Ultrasound, Butterfly Enterprise and iQ Vet. The company was founded by Jonathan M. Rothberg on January 25, 2011 and is headquartered in Burlington, MA.

Butterfly Network Inc - Ordinary Shares - Class A

Butterfly Network Inc

Butterfly Network is trending as investors react to a significant partnership with Midjourney to integrate its ultrasound-on-chip technology into a new AI-powered full-body scanner. While the community is actively debating the stock's long-term potential as a semiconductor play versus immediate dilution risks and a 'sell-the-news' pullback, the stock has seen heightened volume and volatility as bulls look for a breakthrough of key resistance levels.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending following the announcement of a joint research agreement with Honda, which confirms that another major OEM has validated the company's solid-state battery technology after rigorous testing. The community is actively debating the significance of this partnership, weighing the long-term potential of the technology against frustrations over the lack of immediate commercial-scale revenue.

Keel Infrastructure Corp. engages in building artificial intelligence focused data centers and energy assets. It focuses on infrastructure and energy required to support high-performance computing and artificial intelligence workloads. The company was founded on April 1, 2026 and is headquartered in New York, NY.

Keel Infrastructure Corp.

Keel Infrastructure Corp

Keel Infrastructure Corp (KEEL) is seeing heightened community engagement as investors track upcoming lease announcements and institutional positioning ahead of its Russell 3000 inclusion. Discussions center on the company's pivot from crypto mining to AI-ready data center and power infrastructure, with bulls monitoring site developments as the key catalyst for a potential market re-rating.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Invesco QQQ Trust remains a focal point for investors as the community debates the sustainability of the AI-driven market rally against the backdrop of heightened geopolitical tensions in the Middle East and ongoing trade negotiations. Traders are closely monitoring the interplay between speculative options activity, earnings expectations, and potential shifts in macroeconomic policy.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

SPY is experiencing heightened volatility as market participants weigh conflicting geopolitical headlines regarding Iran and ongoing negotiations over the Strait of Hormuz. Community sentiment is deeply divided, with traders closely monitoring institutional flows and technical support levels while reacting to the frequent release of market-moving news updates.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AMNEAL PHARMACEUTICALS, INC. (AMRX) Hits Fresh High: Is There Still Room to Run?

Amneal (AMRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Guardian Pharmacy Services, Inc. (GRDN) Hit a 52 Week High, Can the Run Continue?

Guardian Pharmacy (GRDN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Guardian Pharmacy Services Q1 Earnings Call Highlights

Guardian Pharmacy Services Q1 Earnings Call Highlights...

Guardian Pharmacy Services (GRDN) Q1 Earnings and Revenues Surpass Estimates

Guardian Pharmacy (GRDN) delivered earnings and revenue surprises of +20.83% and +2.10%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Guardian Pharmacy Services Reports First Quarter 2026 Financial Results; Updates Full-Year Guidance

Guardian Pharmacy Services, Inc. (NYSE: GRDN), one of the nation's leading long-term care ('LTC') pharmacy services companies, announced today its financial results for the first quarter ended March...

Jennison Associates LLC Invests $3.49 Million in Guardian Pharmacy Services, Inc. $GRDN

Jennison Associates LLC purchased a new position in shares of Guardian Pharmacy Services, Inc. (NYSE:GRDN - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 115,961 shares of the company's stock, valued at appro...

Guardian Pharmacy Services to Report Q1 Earnings: What's in the Cards?

GRDN heads into Q1 earnings with revenues seen at $329.7M, as growth trends, vaccine volumes and IRA pricing impacts take center stage.

Stevanato Group (STVN) Reports Next Week: Wall Street Expects Earnings Growth

Stevanato (STVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Guardian Pharmacy Services (GRDN) to Release Quarterly Earnings on Wednesday

Guardian Pharmacy Services (NYSE:GRDN) will be releasing its Q1 2026 earnings after the market closes on Wednesday, May 6. (View Earnings Report at...

Guardian Pharmacy Services (GRDN) Reports Next Week: Wall Street Expects Earnings Growth

Guardian Pharmacy (GRDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Guardian Pharmacy Services, Inc. engages in the provision of client service and resident care to long-term care communities. It offers assisted living and skilled nursing, group homes, behavioral health and organizations that serve individuals with intellectual and developmental disabilities. The company was founded by Fred Burke, David Morris, and Kendall Forbes on July 21, 2003 and is headquartered in Atlanta, GA.

Guardian Pharmacy Services Inc. - Ordinary Shares - Class A

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	$0.26	--	--	N/A
Q1 '26	$0.24	$0.29	20.83%	BEAT
Q4 '25	$0.27	$0.37	38.32%	BEAT
Q3 '25	$0.23	$0.25	6.38%	BEAT
Q2 '25	$0.19	$0.23	18.97%	BEAT

GRDNGuardian Pharmacy Services Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '26

Historical Earnings

Latest GRDN News